In addition, downstream targets of NAT10 could be used as potential biomarkers for melanoma malignancy before chemoresistance and metastasis, and the combination regimen could be considered for use in patients before disease progression, thus highlighting the translational value of our study. Here, NAT10 is linked to melanoma.